Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants
- 1 December 2011
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 31 (12), 1192-1207
- https://doi.org/10.1592/phco.31.12.1192
Abstract
Warfarin is the most commonly prescribed oral anticoagulant. However, it remains a difficult drug to manage mostly because of its narrow therapeutic index and wide interpatient variability in anticoagulant effects. Over the past decade, there has been substantial progress in our understanding of genetic contributions to variable warfarin response, particularly with regard to warfarin dose requirements. The genes encoding for cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) are the major genetic determinants of warfarin pharmacokinetics and pharmacodynamics, respectively. Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also been associated with bleeding risk with warfarin. The CYP4F2 gene influences vitamin K availability and makes minor contributions to warfarin dose requirements. Less is known about genes influencing warfarin response in African‐American patients compared with other racial groups, but this is the focus of ongoing research. Several warfarin pharmacogenetic dosing algorithms and United States Food and Drug Administration—cleared genotyping tests are available for clinical use. Clinical trials are ongoing to determine the clinical utility and cost‐effectiveness of genotype‐guided warfarin dosing. Results from these trials will likely influence clinical uptake and third party payer reimbursement for genotype‐guided warfarin therapy. There is still a lack of pharmacogenetic data for the newly approved oral anticoagulants, dabigatran and rivaroxaban, and with other oral anticoagulants in the research and development pipeline. These data, once known, could be of great importance as routine monitoring parameters for these agents are not available.Keywords
This publication has 96 references indexed in Scilit:
- Genetic Warfarin Dosing: Tables Versus AlgorithmsJournal of the American College of Cardiology, 2011
- The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African AmericansClinical Pharmacology & Therapeutics, 2011
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African AmericansClinical Pharmacology & Therapeutics, 2010
- Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African AmericansThe Pharmacogenomics Journal, 2008
- Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African AmericansClinical Pharmacology & Therapeutics, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish PopulationsAmerican Journal of Human Genetics, 2008
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007